Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced that new data demonstrating the prognostic utility of the Decipher® Prostate genomic classifier were published in JAMA Oncology.

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte's Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer

Veracyte (VCYT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Veracyte (VCYT)

Veracyte has seen a tumultuous 2021 so far. Shares have displayed great volatility and in fact, have seen a big pullback in recent times.

Veracyte: Tumultuous Times

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte received final Medicare coverage policies for Decipher Bladder, a molecular subtyping test for individuals with bladder cancer

Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Upcoming Investor Conferences

CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences

Veracyte Inc (NASDAQ: VCYT) has agreed to acquire HalioDx in a €260 million transaction to accelerate growth and strengthen its position in cancer diagnostics. The deal value consists of approximately €147 million in cash and approximately €113 million in stock.

Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth

Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data to be presented at ASCO demonstrate Veracyte's Afirma Xpression Atlas test identifies clinically relevant gene fusions in thyroid cancer

Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veraycte (VCYT) announced that new data from studies of the company's Decipher Prostate Genomic Classifier will be presented at ASCO 2021.

Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Pivotal Clinical Validation Data at ASCO for Noninvasive Nasal Swab Test in Early Lung Cancer Detection

Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced data at ATS 2021 reinforcing the diagnostic performance and utility of the Envisia Genomic Classifier in ILD diagnosis

Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced new data showing the company's Percepta Genomic Atlas detects known gene variants to help guide lung cancer treatment

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q1 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. Announces CEO Succession Plan -- Bonnie Anderson to Assume Active Role as Executive Chairman; Marc Stapley to Become CEO

Veracyte, Inc. Announces CEO Succession Plan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces First Quarter 2021 Financial Results

Veracyte Announces First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new data relating to the Prosigna® Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking place May 5-8. “New data accepted for presentation at this year's ESMO Breast Cancer Congress provide further evidence for the importance of genomic testing in breast cancer, particularly to help physicians and patients

Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO

Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier (GSC), a novel genomic test, in helping to improve lung cancer diagnosis. The data, based on widely accepted community guidelines for establishing analytical validity, add to the growing body of clinical evidence supporting the use of the Percepta GSC to guide next steps for patients with

Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced data for the company's pulmonology portfolio that will be presented at the American Thoracic Society 2021 International Conference

Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results

Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--The first patient has been enrolled and randomized in Acerta Pharma's ESCALADE trial, which is using Veracyte's LymphMark lymphoma subtyping test.

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test

CareDx

Natera

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

3 Cancer Diagnostic Monster Stocks on Sale

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Appoints Muna Bhanji to Its Board of Directors

News for Veracyte Stock (VCYT)